Lipid nanoparticles, or LNPs, are best known as the delivery system used in the COVID-19 mRNA vaccines given to billions of people worldwide. Scientists are now exploring their potential far beyond ...

Plants are constantly on guard. Their roots are equipped with molecular alarm systems that detect invading microbes and trigger immune responses. Yet beneficial soil fungi routinely enter living root ...

A futuristic “DNA origami” vaccine platform may one day outperform mRNA shots while being easier to produce and distribute. Credit: Shutterstock Scientists have developed a new DNA origami–based ...

Imagine an animal that can regrow its whole body — head, brain, organs, and all — from just a small fragment. This isn’t science fiction; it’s biology. Meet the planarian flatworm, a humble freshwater ...

If you are wondering whether Alnylam Pharmaceuticals' current share price lines up with its underlying worth, you are not alone. This article is built to help you assess that. The stock recently ...

Discover six RNAi biotech companies helping to drive momentum in a field that can precisely target disease at its genetic root.

One of the greatest mysteries of our planet is how a soup of lifeless chemicals transformed into the first living cell. There are several competing theories about where this happened, from frozen ...

DUBLIN and LONDON, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Aerska, a biotechnology company using brain shuttle technology to develop RNA medicines for CNS diseases, today announced the close of a $39 ...

A SanegeneBio researcher at work in the company's lab. Genentech, a member of the Roche Group, will apply SanegeneBio’s RNA interference (RNAi) platform to develop one of the company’s RNAi programs ...

Researchers from Carnegie Mellon University have discovered a way to target RNA that could lead to new treatment options for myotonic dystrophy type 1 (DM1), the most common adult-onset form of ...

- ARO-INHBE in combination with tirzepatide achieved -9.4% weight loss at week 16 in obese patients with type 2 diabetes mellitus, demonstrating an approximately two-fold improvement versus -4.8% on ...